RxDoctor Payments Data

Karishma Ramsubeik, MD

Rheumatology · Jacksonville, FLNPI 1689879165

Payments from drug & device makers

$3,535in general payments, 2019–2025

Across 160 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$787
  • UCB, Inc.$507
  • AstraZeneca$405
  • Novartis$358
  • Pfizer$317
  • Amgen$205
  • plus $956 from 12 others
$2,158in research payments, 2019–2025

Across 11 payments — averaging $196.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$2K

What the payments were for

  • Food & beverage$3,45698%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,535 in reported general payments places this provider in the 35th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$72,583
Medicare patients
222
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxychloroquine Sulfate51$2,392
Leflunomide19$1,559
MethotrexateMethotrexate Sodium87$1,526
Prednisone100$535
Omeprazole25$286
Allopurinol28$222
Folic Acid17$154
Pantoprazole Sodium16$139

Paid to pharmacies, not to this prescriber.

Other rheumatology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →